US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tourmaline Bio

16.42

+0.23001.42%

Post-market: 17.360.9400+5.72%15:43 EDT

Volume:59.08K

Turnover:966.65K

Market Cap:421.80M

PE:-5.10

High:16.52

Open:16.35

Low:16.11

Close:16.19

Loading ...

Overview Company News Filings

Tourmaline Bio Inc. Conducted Annual Stockholders Meeting

Promising Phase 2 Trial Results and Strategic Advantages Justify Buy Rating for Tourmaline Bio

Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential

Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein

MT Newswires Live

Tourmaline Bio Announces Positive Phase 2 Trial Results

Tourmaline Bio Inc. Announces Positive Results from Phase 2 TRANQUILITY Trial of Pacibekitug, Paving Way for Future Cardiovascular and Abdominal Aortic Aneurysm Trials

BRIEF-Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial

Tourmaline Bio announces results from ongoing Phase 2 TRANQUILITY trial

Tourmaline Bio Announces Positive Topline Results From the Ongoing Phase 2 Tranquility Trial Evaluating Pacibekitug in Patients With Elevated High-Sensitivity C-Reactive Protein and Chronic Kidney Disease

THOMSON REUTERS

Tourmaline Bio Inc - Pacibekitug Achieves Significant Hs-Crp Reductions Through Day 90

THOMSON REUTERS

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

Tourmaline Bio’s Promising Clinical Developments and Strategic Expansion Drive Buy Rating

Tourmaline Bio Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Tourmaline Bio Is Maintained at Buy by Chardan Capital

Tourmaline Bio: Strong Financial Position and Promising Phase II Study Results Drive Buy Rating

BRIEF-Tourmaline Bio Reports First Quarter 2025 Financial Results

Tourmaline Bio Q1 EPS $(0.89) Beats $(0.91) Estimate

Tourmaline Bio Inc: Qtrly Net Loss per Share, Basic and Diluted $0.89

THOMSON REUTERS

Tourmaline Bio Inc - Has $275.3 Million Cash Runway Into H2 2027

THOMSON REUTERS

Press Release: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TRML/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TRML","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRML\",,,,,undefined,":{"symbol":"TRML","market":"US","secType":"STK","nameCN":"Tourmaline Bio","latestPrice":16.42,"timestamp":1751562000000,"preClose":16.19,"halted":0,"volume":59083,"hourTrading":{"tag":"盘后","latestPrice":17.36,"preClose":16.42,"latestTime":"15:43 EDT","volume":1086,"amount":18476.56,"timestamp":1751571822189},"delay":0,"floatShares":13897934,"shares":25688479,"eps":-3.218151,"marketStatus":"Market Closed","change":0.23,"latestTime":"07-03 13:00:00 EDT","open":16.35,"high":16.515,"low":16.11,"amount":966650.097458,"amplitude":0.025015,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.218151,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":7,"adr":0,"listingDate":1620360000000,"exchange":"NASDAQ","adjPreClose":16.19,"preHourTrading":{"tag":"盘前","latestPrice":15.75,"preClose":16.19,"latestTime":"08:56 EDT","volume":2,"amount":31.5,"timestamp":1751547396976},"postHourTrading":{"tag":"盘后","latestPrice":17.36,"preClose":16.42,"latestTime":"15:43 EDT","volume":1086,"amount":18476.56,"timestamp":1751571822189},"volumeRatio":0.4676121769847756,"impliedVol":0.584,"impliedVolPercentile":0.16},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRML\",,,,,undefined,":{"symbol":"TRML","floatShares":13897934,"roa":"-19.03%","roe":"-26.14%","lyrEps":-2.888196,"volumeRatio":0.4676121769847756,"shares":25688479,"dividePrice":0,"high":16.515,"amplitude":0.025015,"preClose":16.19,"low":16.11,"week52Low":11.56,"pbRate":"1.51","week52High":29.7883,"institutionHeld":0,"latestPrice":16.42,"eps":-3.218151,"divideRate":0,"volume":59083,"delay":0,"ttmEps":-3.218151,"open":16.35,"prevYearClose":20.28,"prevWeekClose":16.54,"prevMonthClose":15.99,"prevQuarterClose":15.99,"fiveDayClose":16.71,"twentyDayClose":18.73,"sixtyDayClose":12.62},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TRML\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541898191","title":"Tourmaline Bio Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541898191","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541898191?lang=en_us&edition=fundamental","pubTime":"2025-06-07 04:07","pubTimestamp":1749240426,"startTime":"0","endTime":"0","summary":"Tourmaline Bio Inc. held its annual meeting of stockholders on June 4, 2025. During the meeting, stockholders voted on the election of Dr. Caley Castelein and Aaron Kantoff as Class I directors to the board of directors, and both were elected. Additionally, the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tourmaline Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and is solely responsible for the information contained","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL6gK39Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRML","BK4539","BK4139"],"gpt_icon":0},{"id":"2538450836","title":"Promising Phase 2 Trial Results and Strategic Advantages Justify Buy Rating for Tourmaline Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2538450836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538450836?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:15","pubTimestamp":1748340958,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio (TRML – Research Report) today and set a price target of $50.00. Yi Chen ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-phase-2-trial-results-and-strategic-advantages-justify-buy-rating-for-tourmaline-bio?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-phase-2-trial-results-and-strategic-advantages-justify-buy-rating-for-tourmaline-bio?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRML"],"gpt_icon":0},{"id":"2536464971","title":"Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2536464971","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536464971?lang=en_us&edition=fundamental","pubTime":"2025-05-20 23:15","pubTimestamp":1747754114,"startTime":"0","endTime":"0","summary":"Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Tourmaline Bio (TRML – Research Report) and keeping the price target at $58.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-tourmaline-bio-driven-by-promising-clinical-results-and-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-tourmaline-bio-driven-by-promising-clinical-results-and-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRML"],"gpt_icon":0},{"id":"2536646479","title":"Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein","url":"https://stock-news.laohu8.com/highlight/detail?id=2536646479","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536646479?lang=en_us&edition=fundamental","pubTime":"2025-05-20 22:41","pubTimestamp":1747752117,"startTime":"0","endTime":"0","summary":"Tourmaline Bio  said Tuesday its Tranquility phase 2 trial assessing monthly and quarterly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein, or hs-CRP, showed \"rapid, deep and durable\" reductions in hs-CRP levels through day 90.Tranquility is a multicenter, randomized, double-blind, placebo-controlled phase 2 trial in patients with elevated hs-CRP, a biomarker associated with elevated cardiovascular risk and chronic kidney disease, and CKD stage 3 or 4. A total of 143 participants were enrolled in the trial, and 126 participants comprised the primary analysis population.The company said the trial is the starting point of the clinical development program for pacibekitug, an anti-IL-6 monoclonal antibody developed by the company, to treat atherosclerotic cardiovascular disease and other cardiovascular diseases.The trial results support the progress of pacibekitug into a planned phase 3 cardiovascular outcomes trial in atherosclerotic cardio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TRML","BK4539"],"gpt_icon":0},{"id":"2536015648","title":"Tourmaline Bio Announces Positive Phase 2 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2536015648","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536015648?lang=en_us&edition=fundamental","pubTime":"2025-05-20 21:29","pubTimestamp":1747747756,"startTime":"0","endTime":"0","summary":"Tourmaline Bio ( ($TRML) ) has provided an update. On May 20, 2025, Tourmaline Bio announced positive topline results from its ongoing Phase 2 TRAN...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tourmaline-bio-announces-positive-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tourmaline-bio-announces-positive-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRML","BK4539","BK4139"],"gpt_icon":0},{"id":"2536104796","title":"Tourmaline Bio Inc. Announces Positive Results from Phase 2 TRANQUILITY Trial of Pacibekitug, Paving Way for Future Cardiovascular and Abdominal Aortic Aneurysm Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2536104796","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536104796?lang=en_us&edition=fundamental","pubTime":"2025-05-20 21:03","pubTimestamp":1747746225,"startTime":"0","endTime":"0","summary":"Tourmaline Bio Inc. Announces Positive Results from Phase 2 TRANQUILITY Trial of Pacibekitug, Paving Way for Future Cardiovascular and Abdominal Aortic Aneurysm Trials. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tourmaline Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL5q5bcr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","TRML"],"gpt_icon":0},{"id":"2536612940","title":"BRIEF-Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2536612940","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536612940?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:10","pubTimestamp":1747743046,"startTime":"0","endTime":"0","summary":"BRIEF-Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY TrialMay 20 (Reuters) - Tourmaline Bio Inc TRML.O:TOURMALINE BIO ANNOUNCES POSITIVE TOPLINE RESULTS FROM TH","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nTUA39HV9Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRML","BK4139","BK4539"],"gpt_icon":0},{"id":"2536145836","title":"Tourmaline Bio announces results from ongoing Phase 2 TRANQUILITY trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2536145836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536145836?lang=en_us&edition=fundamental","pubTime":"2025-05-20 19:35","pubTimestamp":1747740936,"startTime":"0","endTime":"0","summary":"Tourmaline Bio (TRML) announced positive topline results from its ongoing Phase 2 TRANQUILITY trial evaluating quarterly and monthly subcutaneous d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tourmaline-bio-announces-results-from-ongoing-phase-2-tranquility-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tourmaline-bio-announces-results-from-ongoing-phase-2-tranquility-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","TRML","BK4139"],"gpt_icon":0},{"id":"2536661103","title":"Tourmaline Bio Announces Positive Topline Results From the Ongoing Phase 2 Tranquility Trial Evaluating Pacibekitug in Patients With Elevated High-Sensitivity C-Reactive Protein and Chronic Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2536661103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536661103?lang=en_us&edition=fundamental","pubTime":"2025-05-20 19:30","pubTimestamp":1747740600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nTUA39HV9Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","TRML","BK4139"],"gpt_icon":0},{"id":"2536611044","title":"Tourmaline Bio Inc - Pacibekitug Achieves Significant Hs-Crp Reductions Through Day 90","url":"https://stock-news.laohu8.com/highlight/detail?id=2536611044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536611044?lang=en_us&edition=fundamental","pubTime":"2025-05-20 19:30","pubTimestamp":1747740600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nTUA39HV9Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRML","BK4539","BK4139"],"gpt_icon":0},{"id":"2536992617","title":"Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2536992617","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536992617?lang=en_us&edition=fundamental","pubTime":"2025-05-20 19:30","pubTimestamp":1747740600,"startTime":"0","endTime":"0","summary":"– Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/05/20/3084742/0/en/Tourmaline-Bio-Announces-Positive-Topline-Results-from-the-Ongoing-Phase-2-TRANQUILITY-Trial-Evaluating-Pacibekitug-in-Patients-with-Elevated-High-Sensitivity-C-reactive-Protein-an.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ITT","LU0053671581.USD","AAA","LU0054578231.USD","BK4139","BK4161","TRML"],"gpt_icon":0},{"id":"2533640267","title":"Tourmaline Bio’s Promising Clinical Developments and Strategic Expansion Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2533640267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533640267?lang=en_us&edition=fundamental","pubTime":"2025-05-07 13:16","pubTimestamp":1746594982,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith maintained a Buy rating on Tourmaline Bio (TRML – Research Report) on May 5 and set a price target of $49.00....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tourmaline-bios-promising-clinical-developments-and-strategic-expansion-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tourmaline-bios-promising-clinical-developments-and-strategic-expansion-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRML"],"gpt_icon":0},{"id":"2533588447","title":"Tourmaline Bio Price Target Maintained With a $50.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2533588447","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533588447?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:19","pubTimestamp":1746443940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TRML/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2025 07:19 ET (11:19 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRML"],"gpt_icon":0},{"id":"2533258850","title":"Tourmaline Bio Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2533258850","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533258850?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:11","pubTimestamp":1746443460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TRML/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2025 07:11 ET (11:11 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRML"],"gpt_icon":0},{"id":"2532058878","title":"Tourmaline Bio: Strong Financial Position and Promising Phase II Study Results Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2532058878","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532058878?lang=en_us&edition=fundamental","pubTime":"2025-05-03 02:05","pubTimestamp":1746209115,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on TRML stock, giving a Buy rating on April 23. Rami Katkhuda has given h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tourmaline-bio-strong-financial-position-and-promising-phase-ii-study-results-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tourmaline-bio-strong-financial-position-and-promising-phase-ii-study-results-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRML"],"gpt_icon":0},{"id":"2532448658","title":"BRIEF-Tourmaline Bio Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532448658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532448658?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:44","pubTimestamp":1746193440,"startTime":"0","endTime":"0","summary":"BRIEF-Tourmaline Bio Reports First Quarter 2025 Financial ResultsMay 2 (Reuters) - Tourmaline Bio Inc TRML.O:TOURMALINE BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTST","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nTUA2LMFZ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRML"],"gpt_icon":0},{"id":"2532817087","title":"Tourmaline Bio Q1 EPS $(0.89) Beats $(0.91) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2532817087","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532817087?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:33","pubTimestamp":1746185611,"startTime":"0","endTime":"0","summary":"Tourmaline Bio (NASDAQ:TRML) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(0.91) by 2.2 percent. This is a 61.82 percent decrease over losses of $(0.55) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45163001/tourmaline-bio-q1-eps-0-89-beats-0-91-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRML"],"gpt_icon":0},{"id":"2532381706","title":"Tourmaline Bio Inc: Qtrly Net Loss per Share, Basic and Diluted $0.89","url":"https://stock-news.laohu8.com/highlight/detail?id=2532381706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532381706?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:30","pubTimestamp":1746185400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nTUA2LMFZ5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRML","BK4139"],"gpt_icon":0},{"id":"2532177998","title":"Tourmaline Bio Inc - Has $275.3 Million Cash Runway Into H2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2532177998","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532177998?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:30","pubTimestamp":1746185400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nTUA2LMFZ5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TRML"],"gpt_icon":0},{"id":"2532757817","title":"Press Release: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2532757817","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532757817?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:30","pubTimestamp":1746185400,"startTime":"0","endTime":"0","summary":"-- Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 --. -- Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data --. -- Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 --. \"We continue to see growing evidence and enthusiasm for the potential of addressing IL-6-driven cardiovascular inflammation through our discussions with cardiovascular disease experts, attendance at major medical conferences, and review of constantly emerging scientific literature,\" said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. \"We look forward to the expected presentation of topline data from our Phase 2 TRANQUILITY trial of pacibeki","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRML","BK4139","AAA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TRML\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-02","symbol":"TRML","fiscalQuarterEnding":"2025/03","expectedEps":-0.91,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746158400000,"reportTimeType":"pre","actualEps":-0.89},{"market":"US","date":"2025-03-13","symbol":"TRML","fiscalQuarterEnding":"2024/12","expectedEps":-0.91,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"pre","actualEps":-0.86},{"market":"US","date":"2024-11-07","symbol":"TRML","fiscalQuarterEnding":"2024/09","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.78},{"market":"US","date":"2024-08-08","symbol":"TRML","fiscalQuarterEnding":"2024/06","expectedEps":-0.72,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2024-05-13","symbol":"TRML","fiscalQuarterEnding":"2024/03","expectedEps":-0.68,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"pre","actualEps":-0.55}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TRML\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TRML\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3636,"buy":0.6364,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":11,"updateTime":1745467200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TRML\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TRML","date":"2025-07-03","current":-5.090019,"percent":0.9125,"low":-34.281816,"twenty":-13.942291,"median":-9.040368,"eighty":-5.91924,"high":-4.245235,"avg":-11.021549,"sd":6.771314,"marketCap":421804825},"quantilePoints":[{"date":"2023-10-27","current":-8.71976,"twenty":-8.71976,"median":-8.71976,"eighty":-8.71976,"marketCap":266004990},{"date":"2023-11-03","current":-11.48635,"twenty":-11.479684,"median":-10.446378,"eighty":-9.333076,"marketCap":350402598},{"date":"2023-11-10","current":-10.793036,"twenty":-11.186358,"median":-10.579708,"eighty":-9.899727,"marketCap":329252354},{"date":"2023-11-17","current":-10.986364,"twenty":-10.99303,"median":-10.829702,"eighty":-10.326382,"marketCap":335150019},{"date":"2023-11-24","current":-11.615227,"twenty":-11.031696,"median":-10.76637,"eighty":-10.248203,"marketCap":396567073},{"date":"2023-12-01","current":-11.168487,"twenty":-11.229245,"median":-10.866367,"eighty":-10.342382,"marketCap":381314493},{"date":"2023-12-08","current":-10.870661,"twenty":-11.3174,"median":-10.953031,"eighty":-10.4513,"marketCap":371146107},{"date":"2023-12-15","current":-11.376966,"twenty":-11.3174,"median":-10.971922,"eighty":-10.506121,"marketCap":388432364},{"date":"2023-12-22","current":-11.990488,"twenty":-11.334079,"median":-11.000345,"eighty":-10.56642,"marketCap":409379240},{"date":"2023-12-29","current":-16.463839,"twenty":-11.448127,"median":-11.049357,"eighty":-10.624611,"marketCap":562108405},{"date":"2024-01-05","current":-15.832448,"twenty":-11.615227,"median":-11.12977,"eighty":-10.691965,"marketCap":540551426},{"date":"2024-01-12","current":-17.86958,"twenty":-14.057403,"median":-11.275705,"eighty":-10.739704,"marketCap":610103190},{"date":"2024-01-19","current":-18.042319,"twenty":-15.794326,"median":-11.3174,"eighty":-10.78237,"marketCap":616000854},{"date":"2024-01-26","current":-28.247663,"twenty":-17.245336,"median":-11.3174,"eighty":-10.802718,"marketCap":964431710},{"date":"2024-02-02","current":-25.696339,"twenty":-18.466423,"median":-11.376966,"eighty":-10.854121,"marketCap":877324413},{"date":"2024-02-09","current":-27.221144,"twenty":-19.414702,"median":-11.483017,"eighty":-10.869802,"marketCap":929384294},{"date":"2024-02-16","current":-29.594731,"twenty":-25.820542,"median":-11.615227,"eighty":-10.931224,"marketCap":1010423322},{"date":"2024-02-23","current":-27.386394,"twenty":-26.713376,"median":-11.990488,"eighty":-10.954365,"marketCap":935026252},{"date":"2024-03-01","current":-29.159073,"twenty":-27.368366,"median":-15.618013,"eighty":-10.967032,"marketCap":995549070},{"date":"2024-03-08","current":-31.036911,"twenty":-27.583191,"median":-15.832448,"eighty":-10.980587,"marketCap":1059662225},{"date":"2024-03-15","current":-31.337365,"twenty":-27.849093,"median":-16.776557,"eighty":-10.990364,"marketCap":1069920330},{"date":"2024-03-22","current":-17.418731,"twenty":-27.849093,"median":-17.86958,"eighty":-11.001809,"marketCap":733746622},{"date":"2024-03-28","current":-13.942291,"twenty":-27.737925,"median":-17.089275,"eighty":-11.024339,"marketCap":587305056},{"date":"2024-04-05","current":-13.369987,"twenty":-27.649291,"median":-16.097513,"eighty":-11.066035,"marketCap":563197337},{"date":"2024-04-12","current":-12.237556,"twenty":-27.601219,"median":-15.641839,"eighty":-11.122026,"marketCap":515494830},{"date":"2024-04-19","current":-9.534335,"twenty":-27.587698,"median":-14.761172,"eighty":-11.024339,"marketCap":401624330},{"date":"2024-04-26","current":-9.741339,"twenty":-27.562159,"median":-14.331944,"eighty":-10.964588,"marketCap":410344144},{"date":"2024-05-03","current":-9.692632,"twenty":-27.499064,"median":-13.999847,"eighty":-10.868085,"marketCap":408292423},{"date":"2024-05-10","current":-9.601307,"twenty":-27.413435,"median":-13.936202,"eighty":-10.711061,"marketCap":404445446},{"date":"2024-05-17","current":-8.025737,"twenty":-27.374376,"median":-13.351722,"eighty":-10.398841,"marketCap":384697635},{"date":"2024-05-24","current":-7.308771,"twenty":-27.302266,"median":-12.267998,"eighty":-9.914031,"marketCap":350331312},{"date":"2024-05-31","current":-7.233864,"twenty":-27.215971,"median":-12.121878,"eighty":-9.653666,"marketCap":346740801},{"date":"2024-06-07","current":-7.255266,"twenty":-27.185428,"median":-11.76414,"eighty":-9.572083,"marketCap":347766662},{"date":"2024-06-14","current":-8.881815,"twenty":-27.14603,"median":-11.588489,"eighty":-9.467363,"marketCap":425732049},{"date":"2024-06-21","current":-8.084592,"twenty":-27.109976,"median":-11.483017,"eighty":-9.430834,"marketCap":387518750},{"date":"2024-06-28","current":-7.0787,"twenty":-26.971767,"median":-11.440238,"eighty":-9.386998,"marketCap":339303314},{"date":"2024-07-05","current":-6.86468,"twenty":-26.454986,"median":-11.350161,"eighty":-9.074433,"marketCap":329044710},{"date":"2024-07-12","current":-7.597697,"twenty":-26.409918,"median":-11.3174,"eighty":-8.662445,"marketCap":364180427},{"date":"2024-07-15","current":-7.977582,"twenty":-26.391406,"median":-11.3174,"eighty":-8.3885,"marketCap":382389449},{"date":"2024-08-02","current":-8.742702,"twenty":-26.372893,"median":-11.3174,"eighty":-8.456986,"marketCap":419063957},{"date":"2024-08-09","current":-7.563763,"twenty":-26.068949,"median":-11.287618,"eighty":-8.103854,"marketCap":372825418},{"date":"2024-08-16","current":-7.111185,"twenty":-25.449967,"median":-11.168487,"eighty":-7.996844,"marketCap":350517432},{"date":"2024-08-23","current":-7.407701,"twenty":-24.869472,"median":-11.028509,"eighty":-7.771053,"marketCap":365133009},{"date":"2024-08-30","current":-8.968313,"twenty":-24.475141,"median":-10.986364,"eighty":-7.803156,"marketCap":442057098},{"date":"2024-09-06","current":-8.32326,"twenty":-24.06836,"median":-10.959698,"eighty":-7.825628,"marketCap":410261808},{"date":"2024-09-13","current":-9.264829,"twenty":-22.445383,"median":-10.872215,"eighty":-7.866292,"marketCap":456672675},{"date":"2024-09-20","current":-11.756605,"twenty":-20.29746,"median":-10.870661,"eighty":-7.979091,"marketCap":579494803},{"date":"2024-09-27","current":-12.927063,"twenty":-19.046589,"median":-10.935322,"eighty":-7.99325,"marketCap":637187870},{"date":"2024-10-04","current":-13.655348,"twenty":-18.735659,"median":-10.971922,"eighty":-8.030017,"marketCap":673085778},{"date":"2024-10-11","current":-14.295199,"twenty":-18.642737,"median":-11.000345,"eighty":-8.047139,"marketCap":704624655},{"date":"2024-10-18","current":-15.153535,"twenty":-18.505737,"median":-11.091052,"eighty":-8.05463,"marketCap":746932904},{"date":"2024-10-25","current":-14.22237,"twenty":-18.394945,"median":-11.231032,"eighty":-8.094223,"marketCap":701034864},{"date":"2024-10-31","current":-13.774995,"twenty":-18.161449,"median":-11.308466,"eighty":-8.132746,"marketCap":678983292},{"date":"2024-11-08","current":-11.103216,"twenty":-18.042319,"median":-11.3174,"eighty":-8.159499,"marketCap":709240100},{"date":"2024-11-15","current":-10.790634,"twenty":-17.86958,"median":-11.3174,"eighty":-8.214017,"marketCap":689273356},{"date":"2024-11-22","current":-9.120655,"twenty":-17.418731,"median":-11.275705,"eighty":-8.320014,"marketCap":582600099},{"date":"2024-11-29","current":-10.453427,"twenty":-17.155166,"median":-11.168487,"eighty":-8.322611,"marketCap":667733564},{"date":"2024-12-06","current":-9.646538,"twenty":-16.588926,"median":-11.070204,"eighty":-8.356553,"marketCap":616191918},{"date":"2024-12-13","current":-9.040368,"twenty":-16.38283,"median":-10.99303,"eighty":-8.47724,"marketCap":577471577},{"date":"2024-12-20","current":-8.165235,"twenty":-15.938474,"median":-10.96581,"eighty":-8.356553,"marketCap":521570687},{"date":"2024-12-27","current":-8.76739,"twenty":-15.803856,"median":-10.935322,"eighty":-8.34823,"marketCap":560034602},{"date":"2025-01-03","current":-8.285666,"twenty":-15.727613,"median":-10.872215,"eighty":-8.294497,"marketCap":529263470},{"date":"2025-01-10","current":-8.028746,"twenty":-15.632309,"median":-10.835753,"eighty":-8.286469,"marketCap":512852200},{"date":"2025-01-17","current":-6.956908,"twenty":-15.506057,"median":-10.790634,"eighty":-8.144818,"marketCap":444386431},{"date":"2025-01-24","current":-7.029167,"twenty":-15.153535,"median":-10.691965,"eighty":-8.084592,"marketCap":449002101},{"date":"2025-01-31","current":-6.583572,"twenty":-15.019926,"median":-10.527506,"eighty":-8.028746,"marketCap":420538804},{"date":"2025-02-07","current":-6.017545,"twenty":-14.820605,"median":-10.47753,"eighty":-7.976559,"marketCap":384382723},{"date":"2025-02-14","current":-5.254814,"twenty":-14.737372,"median":-10.453427,"eighty":-7.815984,"marketCap":335661764},{"date":"2025-02-21","current":-4.965779,"twenty":-14.726968,"median":-10.377826,"eighty":-7.723969,"marketCap":317199085},{"date":"2025-02-28","current":-5.134383,"twenty":-14.722286,"median":-10.300881,"eighty":-7.572086,"marketCap":327968981},{"date":"2025-03-07","current":-5.752596,"twenty":-14.70512,"median":-10.18045,"eighty":-7.459722,"marketCap":367458601},{"date":"2025-03-14","current":-5.978414,"twenty":-14.542126,"median":-10.060741,"eighty":-7.427006,"marketCap":437679710},{"date":"2025-03-21","current":-5.922279,"twenty":-14.497547,"median":-9.979906,"eighty":-7.330173,"marketCap":433570041},{"date":"2025-03-28","current":-5.869652,"twenty":-14.468597,"median":-9.843242,"eighty":-7.305561,"marketCap":429717227},{"date":"2025-04-04","current":-4.603098,"twenty":-14.357888,"median":-9.76419,"eighty":-7.260688,"marketCap":336992828},{"date":"2025-04-11","current":-4.245235,"twenty":-14.302548,"median":-9.646538,"eighty":-7.232265,"marketCap":310793690},{"date":"2025-04-17","current":-5.094283,"twenty":-14.285835,"median":-9.637837,"eighty":-7.153081,"marketCap":372952429},{"date":"2025-04-25","current":-6.076651,"twenty":-14.263987,"median":-9.604351,"eighty":-7.063704,"marketCap":444871630},{"date":"2025-05-02","current":-6.262368,"twenty":-14.234855,"median":-9.562236,"eighty":-6.926438,"marketCap":458467950},{"date":"2025-05-09","current":-4.879227,"twenty":-14.172431,"median":-9.534236,"eighty":-6.821271,"marketCap":404336659},{"date":"2025-05-16","current":-4.811029,"twenty":-14.114168,"median":-9.455187,"eighty":-6.61259,"marketCap":398685194},{"date":"2025-05-23","current":-4.733532,"twenty":-14.07379,"median":-9.435349,"eighty":-6.497664,"marketCap":392263074},{"date":"2025-05-30","current":-5.117918,"twenty":-14.057743,"median":-9.394303,"eighty":-6.409855,"marketCap":424116788},{"date":"2025-06-06","current":-5.855692,"twenty":-14.031834,"median":-9.322051,"eighty":-6.202372,"marketCap":485255368},{"date":"2025-06-13","current":-6.168781,"twenty":-13.987239,"median":-9.212186,"eighty":-6.076651,"marketCap":511200732},{"date":"2025-06-20","current":-5.217115,"twenty":-13.970758,"median":-9.168591,"eighty":-6.021603,"marketCap":432337101},{"date":"2025-06-27","current":-5.179916,"twenty":-13.942291,"median":-9.120655,"eighty":-5.974473,"marketCap":429254484},{"date":"2025-07-03","current":-5.090019,"twenty":-13.942291,"median":-9.040368,"eighty":-5.91924,"marketCap":421804825}],"updateTime":1751775978052}}}